Free tool
FAERS Monitor: Vonjo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208712 or its brand name (Vonjo, Pacritinib Citrate). Reports on generic versions are filed under their own applications.
Reports
3,069
Serious
1,125
37% of reports
Hospitalization
571
Death reported
350
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea651
- off label use623
- fatigue388
- product dose omission issue337
- death314
- nausea304
- platelet count decreased297
- haemoglobin decreased213
- asthenia158
- dizziness132
- drug ineffective119
- splenomegaly109
- vomiting101
- constipation94
- dyspnoea89
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 9 |
| 2022 | 421 |
| 2023 | 1,102 |
| 2024 | 750 |
| 2025 | 493 |
| 2026 | 288 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,090 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| splenomegalySignal | 109 | 64.3 | 53.4 | 6,673 |
| platelet count decreasedSignal | 297 | 19.1 | 17.2 | 5,102 |
| haemoglobin decreasedSignal | 213 | 14.2 | 12.5 | 2,617 |
| product dose omission issueSignal | 337 | 7.9 | 7.1 | 2,038 |
| diarrhoeaSignal | 651 | 6.9 | 6.5 | 3,390 |
| off label useSignal | 623 | 4.9 | 4.5 | 1,999 |
| fatigueSignal | 388 | 3.4 | 3.1 | 686 |
| constipationSignal | 94 | 3.0 | 2.4 | 121 |
| astheniaSignal | 158 | 2.9 | 2.5 | 196 |
| nauseaSignal | 304 | 2.6 | 2.4 | 318 |
| deathSignal | 314 | 2.5 | 2.2 | 293 |
| dizziness | 132 | 1.8 | 1.5 | 49 |
| vomiting | 101 | 1.5 | 1.2 | 15 |
| dyspnoea | 89 | 1.1 | 0.9 | 0 |
| drug ineffective | 119 | 0.6 | 0.5 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.